NK cell treatment with chemo after lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new type of immune cell therapy called PANK-003, given alongside standard chemotherapy after surgery for stage IIIA non-small cell lung cancer (NSCLC). It aims to see if this combination can help prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have stage IIIA non-small cell lung cancer and have had surgery to remove all visible cancer (R0 resection), followed by standard chemotherapy.
- Your cancer does not have certain gene mutations (EGFR or ALK) that would make other targeted treatments possible.
- Your overall health is good, with a performance status score of 0 or 1 (able to carry out daily activities without help).
- Your blood counts and organ function (kidneys, liver) meet specific levels, as checked by blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental NK cell therapy (PANK-003) given along with standard chemotherapy after surgery for solid tumors. The goal is to see if adding these immune cells can help prevent the cancer from coming back.
This trial tests adding natural killer (NK) cell therapy to standard chemo and immunotherapy before surgery for stage IB to IIIA non-small cell lung cancer that can be removed. It aims to see if this combination helps shrink tumors and improve outcomes.
This trial tests whether adding natural killer (NK) cell therapy to standard chemotherapy after surgery can help prevent pancreatic or bile duct cancer from coming back. It is for patients who have had their tumor completely removed and are now ready for adjuvant chemotherapy.
This trial tests a new approach for people with certain advanced non-small cell lung cancer (NSCLC) that has spread to lymph nodes in the chest but might still be removed. It combines a short course of high-precision radiation, immunotherapy (sintilimab), and standard chemotherapy before surgery to see if it can improve outcomes.
This trial tests if LM103, given after surgery and standard chemotherapy, helps prevent non-small cell lung cancer from coming back. It is for people who have already had chemotherapy or immunotherapy before surgery and whose cancer did not return after surgery.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Stage IIIA Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.